Soligenix closed at $0.35 on Nov 4, down 1.49%, 78.7% below its 52-week closing high. Volume of 77.9K shares was 0.70× its 20-day average (below normal).
Split-adjusted performance: -2.0% over one month, +6.0% over six months, -76.1% over one year.
Short interest was 162.9K shares at the Oct 15 settlement, down 3.0% from the prior report (0.8% of float, 1.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SNGXSoligenix | $0.3508 | −1.49% | +6.0% | — | — | — | $7.6M | |
| ALZNAlzamend Neuro | $1.53 | +4.79% | +39.1% | — | — | — | $7.4M | Compare |
| KPRXKiora Pharmaceuticals | $1.66 | −4.05% | −33.9% | — | — | — | $7.3M | Compare |
| ENSCEnsysce Biosciences | $0.3697 | −2.12% | −5.2% | −15.1% | −220.8% | — | $7.2M | Compare |
| VTGNVistagen Therapeutics | $0.1843 | +9.70% | −69.8% | +504.9% | −882.8% | — | $8.2M | Compare |
| NAIINatural Alternatives International | $1.10 | +3.77% | −59.6% | +1.9% | −39.2% | — | $6.9M | Compare |
| FBLGFibroBiologics | $0.9685 | −2.17% | −24.9% | — | — | — | $6.9M | Compare |
| LEXXLexaria Bioscience | $4.07 | +0.99% | −59.8% | −100.0% | — | — | $8.6M | Compare |
| MBRXMoleculin Biotech | $8.46 | +1.93% | −82.9% | — | — | — | $8.6M | Compare |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
